top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


Integrating Teams After M&A or Strategic Partnerships
Value is driven by what happens bringing together individuals and teams In life sciences, mergers, carve‑outs and strategic alliances are now core to how pipelines advance and products reach patients. But while the deal thesis is usually about science, assets and markets, value is delivered (or destroyed) by what happens with people and ways of working in the first 12–18 months. This year has seen so many significant acquisition, across biotech and medtech, a few of the most
sharonshieldsconsu
Nov 126 min read


Autumn Inflection Point: Approvals, AI, & Capital Put Life Sciences in Overdrive
Autumn inflection point: approvals, AI, and capital are putting life sciences into overdrive. As summer turns to fall, the sector is accelerating, not slowing—driven by a cluster of FDA approvals in high‑unmet‑need diseases, breakthrough gene therapies, new guidance for AI‑enabled and microbiome-based technologies, and rising deal and funding activity. For biopharma leaders and investors, this late‑summer surge signals a pivotal moment to engage, partner, and deploy capital a
sharonshieldsconsu
Aug 296 min read


Patient Advocacy: A Strategic Partner in Rare Disease Commercialisation
Rare Disease as a Strategic Growth Engine Rare disease is no longer just a scientific or regulatory story — it is a commercial one. But in rare disease, “the market” is not an abstract concept. It is a small, tightly connected ecosystem of patients, caregivers, advocates, clinicians, and payers who all know each other — and who expect to be true partners. Speaking to many global commercial leader over the last few weeks Patient advocacy has been a re-occurring theme. For glob
sharonshieldsconsu
Aug 225 min read


Rare Disease Is No Longer a Niche — It's a Strategic Commercial Priority
Rare disease is no longer a niche topic — it has become a strategic priority
for global commercial leaders and asset teams.
As regulatory momentum builds and companies refine how they identify patients,
generate evidence, and shape markets, rare disease is increasingly where scientific
innovation and commercial differentiation meet.
sharonshieldsconsu
Aug 164 min read
bottom of page